I-Mab Sponsored ADR (NASDAQ:IMAB - Get Free Report) has been given an average rating of "Moderate Buy" by the eight brokerages that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $7.6667.

Several equities analysts have recently commented on IMAB shares. Leerink Partners started coverage on shares of I-Mab in a report on Friday, October 3rd. They set an "outperform" rating and a $9.00 price target on the stock. Wall Street Zen cut shares of I-Mab from a "buy" rating to a "hold" rating in a report on Sunday, October 19th. Citigroup restated a "buy" rating on shares of I-Mab in a report on Monday. Weiss Ratings restated a "sell (d+)" rating on shares of I-Mab in a report on Wednesday, October 8th. Finally, Brookline Capital Management restated a "buy" rating on shares of I-Mab in a report on Thursday, August 28th.

View Our Latest Analysis on I-Mab

I-Mab Stock Up 11.4%

Shares of NASDAQ:IMAB opened at $4.70 on Tuesday. The company's fifty day moving average is $4.46 and its two-hundred day moving average is $2.81. I-Mab has a 12-month low of $0.60 and a 12-month high of $6.79. The company has a market cap of $383.80 million, a P/E ratio of -13.06 and a beta of 1.45.

I-Mab (NASDAQ:IMAB - Get Free Report) last posted its quarterly earnings results on Wednesday, August 20th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.03. Equities research analysts anticipate that I-Mab will post -0.56 earnings per share for the current year.

Institutional Investors Weigh In On I-Mab

Large investors have recently bought and sold shares of the business. Ground Swell Capital LLC bought a new stake in I-Mab in the first quarter worth $53,000. Stonepine Capital Management LLC bought a new stake in I-Mab in the first quarter worth $398,000. Geode Capital Management LLC boosted its holdings in I-Mab by 147.6% in the second quarter. Geode Capital Management LLC now owns 54,562 shares of the company's stock worth $132,000 after purchasing an additional 32,525 shares in the last quarter. Finally, SG Americas Securities LLC boosted its holdings in I-Mab by 6.6% in the second quarter. SG Americas Securities LLC now owns 876,353 shares of the company's stock worth $2,121,000 after purchasing an additional 54,312 shares in the last quarter. 38.38% of the stock is currently owned by institutional investors.

I-Mab Company Profile

(Get Free Report)

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.

Featured Articles

• Five stocks we like better than I-Mab
• How to invest in marijuana stocks in 7 steps
• Growth Picks: 3 Low-Cost Stocks That Could Double in Value
• What Are Growth Stocks and Investing in Them
• Are These 3 Beaten-Down Stocks Ready to Rebound?
• Trading Stocks: RSI and Why it's Useful
• Does the Trump-Induced Quantum Stock Rally Have Legs?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in I-Mab Right Now?

Before you consider I-Mab, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and I-Mab wasn't on the list.

While I-Mab currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here